Failure of alefacept in the treatment of vitiligo

Journal of Drugs in Dermatology

Volumn 12, Issue 2, 2013, Pages 159-161

  Dayel, Salman Bin ^a   AlGhamdi, Khalid ^b  

^a PRINCE SATTAM BIN ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CORTICOSTEROID; TACROLIMUS;

ADULT; ARTICLE; BODY SURFACE; CASE REPORT; DEPIGMENTATION; DIGITAL IMAGING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; INFORMED CONSENT; LABORATORY TEST; MALE; PILOT STUDY; TREATMENT DURATION; TREATMENT OUTCOME; VITILIGO;

ADOLESCENT; ADULT; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRAMUSCULAR; MALE; PILOT PROJECTS; RECOMBINANT FUSION PROTEINS; SKIN; TREATMENT FAILURE; VITILIGO; YOUNG ADULT;

EID: 84873349219     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Srivastava G. Vitiligo update. Asian Clin Dermatol. 1994;1:1-4.
2. Papadopoulos L, Bor R, Legg C. Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioral therapy. Br J Med Psychol. 1999;72(Pt 3):385-396.
3. Schmid-Ott G, Künsebeck HW, Jecht E, et al. Stigmatization experience, coping and sense of coherence in vitiligo patients. J Eur Acad Dermatol Venereol. 2007;21(4):456-461.
4. Porter JR, Beuf AH, Lerner AB, Nordlund JJ. The effect of vitiligo on sexual relationships. J Am Acad Dermatol. 1990;22(2 Pt 1):221-222.
5. Halder RM, Chappell JL. Vitiligo update. Semin Cutan Med Surg. 2009;28(2):86-92.
6. Passeron T, Ortonne JP. Physiopathology and genetics of vitiligo. J Autoimmun. 2005;25 suppl:63-68.
7. Iacovelli P, Sinagra JL, Vidolin AP, et al. Relevance of thyroiditis and of other autoimmune disease in children with vitiligo. Dermatology. 2005;210(1):26-30.
8. Göktay F, Mansur AT, Aydingöz; JE. Colocalization of vitiligo and lichen planus on scrotal skin: a finding contrary to the actinic damage theory. Dermatology. 2006;212(4):390-392.
9. Al-Mutairi N, Al-Doukhi A. Familial coexisting and colocalized psoriasis and vitiligo responding to alefacept. J Cutan Med Surg. 2009;13(3):172-175.
10. Chow S, Rizzo C, Ravitskiy L, Sinha AA. The role of T cells in cutaneous autoimmune disease. Autoimmunity. 2005;38(4):303-317.
11. van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, Tigges B, Westerhof W, Das P. Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest. 2000;80(8):1299-1309.
12. Spritz RA. The genetics of generalized vitiligo and associated autoimmune disease. Pigment Cell Res. 2007;20(4):271-278.
13. Norris DA. Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. J Invest Dermatol. 1990;95(6 suppl):111S-120S.
14. Moretti S, Spallanzani A, Amato L, et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res. 2002;15(2):87-92.
15. Abdallah M, Abdel-Nasser MB, Moussa MH, Assaf C, Orfanos CE. Sequential immunohistochemical study of depigmenting and repigmenting minigrafts in vitiligo. Eur J Dermatol. 2003;13(6):548-552.
16. Vaishnaw AK, TenHoor CN. Pharmacokinetics, biological activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn. 2002;29(5-6):415-426.
17. Gottlieb AB. Alefacept is well tolerated in patients with chronic plaque psoriasis. J Cutan Med Surg. 2004;8 suppl 2:14-19.
18. Langley RG, Cherman AM, Gupta AK. Alefacept: an expert review concerning the treatment of psoriasis. Expert Opin Pharmacother. 2005;6(13):2327-2333.